Related Experiment Video
Updated: Jan 16, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
7.6K
Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis
Journal of Drugs in Dermatology : JDD
|October 2, 2025
Summary
Ruxolitinib cream, a nonsteroidal therapy, demonstrated superior efficacy compared to triamcinolone cream for moderate atopic dermatitis. This Janus kinase inhibitor cream offers a well-tolerated alternative to topical corticosteroids.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition often managed with topical corticosteroids.
- There is a significant need for effective nonsteroidal treatments for AD due to potential corticosteroid side effects.
- Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is being investigated as a topical therapy for AD.
Purpose of the Study:
- To compare the efficacy and safety of 1.5% ruxolitinib cream versus 0.1% triamcinolone cream in adults with mild to moderate AD.
- To evaluate the impact of ruxolitinib cream on skin lesion severity and itch.
- To assess the tolerability of topical ruxolitinib in the context of AD treatment.
Main Methods:
- A phase 2, randomized, dose-ranging study comparing 1.5% ruxolitinib cream twice daily with 0.1% triamcinolone cream twice daily for 4 weeks.
- Efficacy endpoints included the Eczema Area and Severity Index (EASI) and Investigator's Global Assessment (IGA) score.
- Itch severity was measured using the numerical rating scale (NRS).
Main Results:
- Significantly more patients achieved $\ge$75% (56.0% vs 47.1%) and $\ge$90% (26.0% vs 13.7%) improvement in EASI with ruxolitinib cream versus triamcinolone cream at week 4.
- Ruxolitinib cream showed superior improvement in IGA scores (38.0% vs 25.5%) and rapid itch reduction (42.5% vs 20.5% on day 2).
- Ruxolitinib cream was well-tolerated, with mild to moderate adverse events, primarily nasopharyngitis and headache.
Conclusions:
- Ruxolitinib cream demonstrated comparable or superior efficacy to midpotency topical corticosteroids for mild to moderate atopic dermatitis.
- It offers a well-tolerated nonsteroidal treatment option, potentially mitigating concerns associated with long-term corticosteroid use.
- Ruxolitinib cream provides rapid itch relief and significant improvement in skin condition for AD patients.
